BioLineRX Ltd

BLRX

...

BLRX: BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Show BLRX Financials

All

Government

Consumer Interest

SEC Filings

ESG/Other

Congress Trading

Recent trades of BLRX by members of U.S. Congress

No Congress Trading data for this ticker

Congress Trading Dashboard

Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by BLRX's directors and management

No recent Insider Trading for this ticker

Insider Trading Dashboard

Corporate Lobbying

Government lobbying spending instances

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

U.S. Patents

New patents grants

No new patents for this ticker

U.S. Patents Dashboard

Government Contracts

Federal grants, loans, and purchases

No Government Contracts for this ticker

Government Contracts Dashboard

Twitter

Followers on BLRX's company Twitter account

WallStreetBets

Number of mentions of BLRX in WallStreetBets Daily Discussion

BLRX News

Recent insights relating to BLRX

CNBC Recommendations

Recent picks made for BLRX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BLRX

Corporate Flights

Flights by private jets registered to BLRX